Profusa, Inc. is leading the development of a new generation of biologically integrated sensors that empowers an individual with the ability to continuously monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Overcoming the body's response to foreign material, the company's technology enables the development of minute bioengineered sensors that become one with the body to detect and transmit clinical-grade data for personal and medical use. The company's first product, the Lumee Oxygen Sensing System™, is slated to be available in Europe in early 2016 for the measurement of tissue-oxygen perfusion in the clinical management of chronic wounds.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/16/15 | $13,200,000 | Series B |
3E Bioventures Qihoo 360 | undisclosed |
| 08/14/18 | $45,000,000 | Series C |
3E Bioventures Atinum Investment Maxim Integrated Ventures Tasly Pharmaceutical Group VMS Investments Group | undisclosed |
